EW · 10-Q · 2026Q2 · Full report
Revenue Performance and Mix
Edwards Lifesciences Corp · 2026-08-04 · Importance 54 · Surprise 40 · No source text
Six-month 2026 net sales increased 15.1% year over year to $3,389.6 million from $2,944.9 million, with TAVR and TMTT driving the $444.7 million increase. TAVR sales rose 12.8% to $2,455.6 million, while TMTT sales increased 49.6% to $373.7 million and Surgical sales increased 8.2% to $560.3 million. International sales increased 19.1% to $1,448.5 million, led by Europe at $882.2 million, Rest of World at $379.3 million, and Japan at $187.0 million. TMTT growth was primarily associated with higher PASCAL, EVOQUE, and SAPIEN M3 sales in the United States and Europe, while TAVR growth reflected higher SAPIEN 3 Ultra RESILIA sales in the United States, Europe, and Japan.
Key facts
- Transcatheter Mitral and Tricuspid Therapies (TMTT) net sales for the three months ended June 30, 2026 were $198.6 million, up $64.1 million (47.7%) from $134.5 million in 2025. source
- TMTT net sales for the six months ended June 30, 2026 were $373.7 million, up $124.0 million (49.6%) from $249.7 million in 2025. source
- Total net sales for the three months ended June 30, 2026 were $1,741.0 million, up $208.8 million (13.6%) from $1,532.2 million in the three months ended June 30, 2025. source
- Total net sales for the six months ended June 30, 2026 were $3,389.6 million, up $444.7 million (15.1%) from $2,944.9 million for the six months ended June 30, 2025. source
- Transcatheter Aortic Valve Replacement (TAVR) net sales for the three months ended June 30, 2026 were $1,258.3 million, up $127.4 million (11.3%) from $1,130.9 million in 2025. source
- TAVR net sales for the six months ended June 30, 2026 were $2,455.6 million, up $278.1 million (12.8%) from $2,177.5 million in 2025. source
- Surgical net sales for the six months ended June 30, 2026 were $560.3 million, up $42.6 million (8.2%) from $517.7 million in 2025. source
- Surgical net sales for the three months ended June 30, 2026 were $284.1 million, up $17.3 million (6.5%) from $266.8 million in 2025. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +25.5% | Total net sales for the six months ended June 30, 2026 were $3,389.6 million, up $444.7 million (15.1%) from $2,944.9 million for the six… |
| revenue | positive | realized | +12.0% | Total net sales for the three months ended June 30, 2026 were $1,741.0 million, up $208.8 million (13.6%) from $1,532.2 million in the… |
| revenue | positive | realized | +7.1% | TMTT net sales for the six months ended June 30, 2026 were $373.7 million, up $124.0 million (49.6%) from $249.7 million in 2025. |
| revenue | positive | realized | +3.7% | Transcatheter Mitral and Tricuspid Therapies (TMTT) net sales for the three months ended June 30, 2026 were $198.6 million, up $64.1… |